TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11491130

Group type: EXPERIMENTAL
Intervention: Educational intervention with an interactive graphic card and verbal reinforcement
Number of subjects: 315

Group type: COMPARATOR
Intervention: Routine information (Control)
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 315
Study: 9756005

Group type: EXPERIMENTAL
Intervention: Initial daily administration of 6 million units of natural interferon-alpha subcutaneously for 2 weeks, then thrice a week for 22 weeks (Group A)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Thrice a week administration of 6 million units of natural interferon-alpha for 26 weeks (Group B)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Initial daily administration of interferon (Group A)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Thrice a week administration of interferon (Group B)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Initial daily administration of interferon (Group A) in patients with genotype 1b
Number of subjects: 105

Group type: COMPARATOR
Intervention: Thrice a week administration of interferon (Group B) in patients with genotype 1b
Number of subjects: 105
Study: 8147101

Group type: EXPERIMENTAL
Intervention: SPf66 malaria vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 3145297

Group type: EXPERIMENTAL
Intervention: GRF 0.05 micrograms/Kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: GRF 0.05 micrograms/Kg + TRH 400 micrograms
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: GRF 0.1 micrograms/Kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: GRF 1 microgram/Kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: GRF 0.05 micrograms/Kg + TRH 20 micrograms
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: GRF 1 microgram/Kg + TRH 400 micrograms
Number of subjects: 6

Group type: COMPARATOR
Intervention: Vehicle (control treatment)
Number of subjects: 6
Study: 30661697

Group type: EXPERIMENTAL
Intervention: Pomegranate juice (PJ) 200 ml/day for 6 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 29055956

Group type: EXPERIMENTAL
Intervention: Higher daily salt intake (2.0 g/day higher compared with normal weight individuals) after multivariable adjustment, 95% CI, 1.2‐2.8 g/day, P < 0.001
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased activity in brain regions (orbitofrontal cortex, insula, parahippocampus)
Number of subjects: 0
Study: 25315830

Group type: EXPERIMENTAL
Intervention: Quetiapine (386.3 mg/day)
Number of subjects: 1098

Group type: COMPARATOR
Intervention: Risperidone (3.2 mg/day)
Number of subjects: 1098

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 1098
Study: 23351822

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 2331

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2331
Study: 21574968

Group type: EXPERIMENTAL
Intervention: Sugammadex 16 mg/kg (Study A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg/kg (Study B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (0.9% saline) (Study A)
Number of subjects: 0
Study: 18956190

Group type: EXPERIMENTAL
Intervention: Bryan Cervical Disc replacement (31 patients)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Anterior cervical fusion with iliac crest autograft and plate (34 patients)
Number of subjects: 65
Study: 16965429

Group type: EXPERIMENTAL
Intervention: Methyl aminolaevulinate-based photodynamic therapy (MAL-PDT) for actinic keratosis (AK)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Methyl aminolaevulinate-based photodynamic therapy (MAL-PDT) for nodular basal cell carcinoma (BCC)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Methyl aminolaevulinate-based photodynamic therapy (MAL-PDT) for superficial basal cell carcinoma (BCC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cryotherapy for actinic keratosis (AK)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Excision surgery for basal cell carcinoma (BCC)
Number of subjects: 12
Study: 15292315

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/d)
Number of subjects: 48

Group type: COMPARATOR
Intervention: No raloxifene (Control)
Number of subjects: 48
Study: 11475456

Group type: EXPERIMENTAL
Intervention: High heeled shoes
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Leather shoes
Number of subjects: 10

Group type: COMPARATOR
Intervention: Running shoes
Number of subjects: 10

Group type: COMPARATOR
Intervention: Flat leather shoes
Number of subjects: 10
Study: 9757419

Group type: EXPERIMENTAL
Intervention: Intravenous rt-PA
Number of subjects: 615

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 615
Study: 7879632

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (various intervention sequences)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 21
Study: 2903817

Group type: EXPERIMENTAL
Intervention: Terfenadine (60 mg twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clemastine
Number of subjects: 0
Study: 29998524

Group type: EXPERIMENTAL
Intervention: C1-inhibitor (C1-INH) subcutaneous (SC) administration, 40 IU/kg twice weekly
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: C1-inhibitor (C1-INH) subcutaneous (SC) administration, 60 IU/kg twice weekly
Number of subjects: 124

Group type: COMPARATOR
Intervention: C1-inhibitor (C1-INH) intravenous (IV) administration, 1000 IU
Number of subjects: 124
Study: 26014092

Group type: EXPERIMENTAL
Intervention: Diclofenac patch applied twice a day for 7 days
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo patch applied twice a day for 7 days
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Diclofenac patch
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 164
Study: 24596084

Group type: EXPERIMENTAL
Intervention: Tonsillectomy combined with steroid pulses
Number of subjects: 72

Group type: COMPARATOR
Intervention: Steroid pulses alone
Number of subjects: 72
Study: 23652861

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 200

Group type: COMPARATOR
Intervention: Noncilostazol (Control)
Number of subjects: 200
Study: 20101454

Group type: EXPERIMENTAL
Intervention: Sexual health seminars for HIV+ MSM
Number of subjects: 675

Group type: COMPARATOR
Intervention: Contrast prevention video arm
Number of subjects: 675
Study: 18215213

Group type: EXPERIMENTAL
Intervention: Topiramate 200 mg/d
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Topiramate 300 mg/d
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 12365887

Group type: EXPERIMENTAL
Intervention: Ketoprofen administered before surgery and regular doses after discharge for 72 hours
Number of subjects: 300

Group type: COMPARATOR
Intervention: Ketoprofen administered at discharge
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Ketoprofen doses after discharge
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Age of the child
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Worst pain at rest
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Worst pain during swallowing
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Fear of separation from parents
Number of subjects: 300
Study: 9656896

Group type: EXPERIMENTAL
Intervention: Manual acupuncture
Number of subjects: 21

Group type: COMPARATOR
Intervention: Low-frequency transcutaneous electrical nerve stimulation (low-TENS)
Number of subjects: 21
Study: 8135325

Group type: EXPERIMENTAL
Intervention: 6.7 mmol (167 mg) magnesium aspartate
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo (Na-aspartate)
Number of subjects: 300
Study: 2572616

Group type: EXPERIMENTAL
Intervention: Azelastine hydrochloride, 8.8 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 827393

Group type: EXPERIMENTAL
Intervention: Pollinex (glutaraldehyde‐pollen‐tyrosine adsorbate)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Alavac-P (alum‐precipitated pyridine extract)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 112
Study: 29098501

Group type: EXPERIMENTAL
Intervention: Intravenous carperitide (0.02 μg/kg/min) in addition to standard treatment
Number of subjects: 260

Group type: COMPARATOR
Intervention: Matching standard treatment
Number of subjects: 260
Study: 25336731

Group type: EXPERIMENTAL
Intervention: Natural A(H1N1)pdm09 infection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inactivated A(H1N1)pdm09 vaccine
Number of subjects: 0
Study: 24409779

Group type: EXPERIMENTAL
Intervention: Modified apocrine gland removal surgery with high radiofrequency knife (Group B)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Traditional apocrine gland removal surgery (Group A)
Number of subjects: 105
Study: 21682864

Group type: EXPERIMENTAL
Intervention: COPE-ICD programme (1-year psycho-educational component + 12-week exercise training)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 196
Study: 19549426

Group type: EXPERIMENTAL
Intervention: Olopatadine 0.6% nasal spray (2 sprays/nostril b.i.d.)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Fluticasone propionate 50 microg nasal spray (2 sprays/nostril q.d.)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Olopatadine 0.6% nasal spray
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Olopatadine 0.6% nasal spray and Fluticasone propionate 50 microg nasal spray
Number of subjects: 130

Group type: COMPARATOR
Intervention: Fluticasone propionate 50 microg nasal spray
Number of subjects: 130
Study: 16432345

Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 14530982

Group type: EXPERIMENTAL
Intervention: Power training (twice a week for 15 weeks)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 23
Study: 11412248

Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted colectomy
Number of subjects: 236

Group type: COMPARATOR
Intervention: Conventional open surgery
Number of subjects: 236
Study: 9401885

Group type: EXPERIMENTAL
Intervention: nDTPw
Number of subjects: 812

Group type: COMPARATOR
Intervention: Triple Antigen
Number of subjects: 812
Study: 8216567

Group type: EXPERIMENTAL
Intervention: naproxen sodium 550 mg twice daily for 10 days
Number of subjects: 120

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 120
Study: 31977324

Group type: EXPERIMENTAL
Intervention: Maximal strength training
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 54
Study: 29483043

Group type: EXPERIMENTAL
Intervention: Everolimus (10 mg/d)
Number of subjects: 0
Study: 27936233

Group type: EXPERIMENTAL
Intervention: Lopinavir-ritonavir (LPV-rtv) based ART with anti-malarial treatment
Number of subjects: 31

Group type: COMPARATOR
Intervention: Nevirapine (NVP) based ART
Number of subjects: 31
Study: 25429720

Group type: EXPERIMENTAL
Intervention: Remifentanil (0.15 μg(‐1)kgIBW(‐1) min(‐1))
Number of subjects: 126

Group type: COMPARATOR
Intervention: Fentanyl (200 to 500 μg as needed)
Number of subjects: 126
Study: 23236595

Group type: EXPERIMENTAL
Intervention: Complex psycho-social intervention program
Number of subjects: 173
Study: 20490354

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment for 4 weeks
Number of subjects: 43
Study: 18577583

Group type: EXPERIMENTAL
Intervention: Asics Nimbus 6
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Brooks Glycerin 3
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (Dunlop Volley)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both neutral-cushioned running shoes
Number of subjects: 22
Study: 16448296

Group type: EXPERIMENTAL
Intervention: Sun-protection program
Number of subjects: 211

Group type: COMPARATOR
Intervention: Stress management (control) program
Number of subjects: 211
Study: 12811362

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (250 mL)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Lime juice (one quarter-strength)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Red wine
Number of subjects: 4

Group type: COMPARATOR
Intervention: Water
Number of subjects: 4
Study: 11225745

Group type: EXPERIMENTAL
Intervention: SIMP (Simplified)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: QUAL (Qualitative)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: QUANT (Quantitative)
Number of subjects: 15

Group type: COMPARATOR
Intervention: All strategies
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: SIMP to QUANT
Number of subjects: 15
Study: 9573887

Group type: EXPERIMENTAL
Intervention: Maxillary expansion and protraction facemask
Number of subjects: 20
Study: 8472828

Group type: EXPERIMENTAL
Intervention: (+/‐)‐telenzepine (3 mg orally at 6 p.m. for 5 days)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 3513692

Group type: EXPERIMENTAL
Intervention: Local radiotherapy (45 Gy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 0
Study: 30807234

Group type: EXPERIMENTAL
Intervention: Palbociclib plus fulvestrant
Number of subjects: 521

Group type: COMPARATOR
Intervention: Placebo plus fulvestrant
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Palbociclib in the POP trial
Number of subjects: 521
Study: 30393030

Group type: EXPERIMENTAL
Intervention: One to one intervention by a nurse including education and exercise training prior to surgery
Number of subjects: 60
Study: 27385377

Group type: EXPERIMENTAL
Intervention: Combined Foley's catheter and vaginal misoprostol
Number of subjects: 210

Group type: COMPARATOR
Intervention: Foley's catheter or low-dose vaginal misoprostol alone
Number of subjects: 210
Study: 24932625

Group type: EXPERIMENTAL
Intervention: intralymphatic immunotherapy (ILIT)
Number of subjects: 112

Group type: COMPARATOR
Intervention: subcutaneous immunotherapy (SCIT)
Number of subjects: 112
Study: 23075021

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20927344

Group type: EXPERIMENTAL
Intervention: Randomized Controlled Trials (RCTs)
Number of subjects: 578

Group type: COMPARATOR
Intervention: Controlled Clinical Trials (CCTs)
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Methodological quality (Jadad score)
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Double-blind studies
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Studies with adequate allocation concealment
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Reporting of withdrawals and losses to follow-up
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Sample size calculations
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Intention-to-treat analysis
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Industry funding
Number of subjects: 578

Group type: COMPARATOR
Intervention: Positive conclusions from industry-funded studies
Number of subjects: 578
Study: 17652881

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of non-expanded peripheral blood mononuclear cells (PBMNCs) within 5 days after PCI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard PCI for similar AMI (Control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of PBMNCs
Number of subjects: 0
Study: 15704689

Group type: EXPERIMENTAL
Intervention: Vardenafil, a phosphodiesterase 5 inhibitor; dosage and duration not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified; no specific control intervention mentioned.
Number of subjects: 0
Study: 12015188

Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg (titrated to 80 mg after 4 weeks)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Enalapril 10 mg (titrated to 20 mg after 4 weeks)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg / Enalapril 10 mg
Number of subjects: 252
Study: 10369630

Group type: EXPERIMENTAL
Intervention: Alternate-day omeprazole therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: On-demand therapy with omeprazole
Number of subjects: 0
Study: 7594361

Group type: EXPERIMENTAL
Intervention: Brief Mental Status Examination (BMSE)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ease of administration of BMSE
Number of subjects: 100
Study: 2267903

Group type: EXPERIMENTAL
Intervention: Arterialization (ART)
Number of subjects: 64
Study: 389354

Group type: EXPERIMENTAL
Intervention: Clotrimazole (local treatment for 6 days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Clotrimazole (local treatment for 6 days) + Nystatin (oral treatment for 10 days)
Number of subjects: 100
Study: 30922282

Group type: EXPERIMENTAL
Intervention: Coaching plus education (9, 20-min telephone-based sessions with a certified coach and 6 webinar-based education sessions focused on physical activity and nutrition)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Education only (6 webinar-based education sessions focused on physical activity and nutrition)
Number of subjects: 50
Study: 28936905

Group type: EXPERIMENTAL
Intervention: Microwave diathermy (MWD) and transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Microwave diathermy (MWD) and placebo TENS
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo MWD and TENS
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo MWD and placebo TENS
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 88
Study: 25801708

Group type: EXPERIMENTAL
Intervention: EADB-100 (Quadruple therapy with esomeprazole, amoxicillin, DOX-100 mg b.i.d., and bismuth subcitrate)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: EADB-200 (Quadruple therapy with esomeprazole, amoxicillin, DOX-200 mg b.i.d., and bismuth subcitrate)
Number of subjects: 103
Study: 23600548

Group type: EXPERIMENTAL
Intervention: 300IR 5-grass pollen sublingual tablet (4M group)
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: 300IR 5-grass pollen sublingual tablet (2M group)
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: 300IR 5-grass pollen sublingual tablet
Number of subjects: 435

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 435
Study: 22193793

Group type: EXPERIMENTAL
Intervention: Peer-led intervention (In Our Own Voice-Family Companion [IOOV-FC])
Number of subjects: 158

Group type: COMPARATOR
Intervention: Clinician-led family education session
Number of subjects: 158
Study: 19125990

Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg
Number of subjects: 191

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study: 17235042

Group type: EXPERIMENTAL
Intervention: BEP + HDCT
Number of subjects: 219

Group type: COMPARATOR
Intervention: BEP alone
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: BEP + HDCT (among patients with unsatisfactory marker decline)
Number of subjects: 219

Group type: COMPARATOR
Intervention: BEP alone (among patients with unsatisfactory marker decline)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: BEP + HDCT and BEP alone (regarding serum tumor marker decline)
Number of subjects: 219
Study: 12641501

Group type: COMPARATOR
Intervention: Conventional 13C-UBT (75 mg 13C-urea)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Tablet-based 13C-UBT (100 mg 13C-urea)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Tablet-based 13C-UBT (50 mg 13C-urea)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional 13C-UBT (75 mg 13C-urea) at follow-up
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Tablet-based 13C-UBT (100 mg 13C-urea) at follow-up
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Tablet-based 13C-UBT (50 mg 13C-urea) at follow-up
Number of subjects: 200
Study: 10704542

Group type: EXPERIMENTAL
Intervention: Extracapsular cataract extraction and posterior chamber lens implantation with trabeculectomy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Extracapsular cataract extraction and posterior chamber lens implantation without trabeculectomy
Number of subjects: 35
Study: 9350364

Group type: EXPERIMENTAL
Intervention: Nalbuphine (Group NAL)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Diphenhydramine (Group DIP)
Number of subjects: 80
Study: 8478759

Group type: EXPERIMENTAL
Intervention: Midazolam (0.35 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazepam (0.70 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3094356

Group type: EXPERIMENTAL
Intervention: Sustained-release nitroglycerin, 13 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Diltiazem, 60 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combination of nitroglycerin and diltiazem
Number of subjects: 15
Study: 31700615

Group type: EXPERIMENTAL
Intervention: IL-1 receptor antagonist (IL-1Ra)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-1Ra
Number of subjects: 0
Study: 29109316

Group type: EXPERIMENTAL
Intervention: Formocresol (FC)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite (NaOCl)
Number of subjects: 40
Study: 26333841

Group type: EXPERIMENTAL
Intervention: Currently available interventions for first-episode schizophrenia; specific interventions not detailed.
Number of subjects: 0
Study: 23335852

Group type: EXPERIMENTAL
Intervention: Calcium dobesilate (CaD) 500 mg daily for 3 months
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 90
Study: 20358358

Group type: EXPERIMENTAL
Intervention: 4 mg IV zoledronic acid
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standard treatment (control)
Number of subjects: 14
Study: 19118117

Group type: EXPERIMENTAL
Intervention: S. aureus bacteremia
Number of subjects: 3359

Group type: EXPERIMENTAL
Intervention: Non-bloodstream S. aureus infections
Number of subjects: 3359
Study: 16636210

Group type: EXPERIMENTAL
Intervention: Ximelagatran, 36 mg twice daily
Number of subjects: 7329

Group type: COMPARATOR
Intervention: Warfarin sodium (target international normalized ratio, 2.0‐3.0)
Number of subjects: 7329
Study: 15646216

Group type: EXPERIMENTAL
Intervention: 18% carbamide peroxide (Group 1)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 16.4% carbamide peroxide (Group 2)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Both groups (Group 1 and Group 2)
Number of subjects: 95